Large-scale production and purification of phage preparations represent
an important new business opportunity
MONTREAL, April 3 /CNW Telbec/ - Biophage Pharma Inc. (TSX.V: BUG)
reports that it has signed a groundbreaking contract with Alberta Agriculture
and food to conduct a pilot study for the large-scale production and
purification of bacteriophage preparations in a biofermentor. Securing this
contract marks the beginning of a new business opportunity for Biophage in
large-scale production of phage preparations. This is highly opportune as
phages have been ruled to be safe for use as food additives.
Biophage has seen a renewed interest in phage therapy since the first
groundbreaking announcement by the US FDA (August 18, 2006) regarding the
safety use of a bacteriophage preparation made of six phages against Listeria
monocytogenes on ready-to-eat meat and poultry products.
Dr Rosemonde Mandeville, President and CEO said: "We are very pleased to
announce Biophage's first contract for the large-scale production of phages in
a biofermentor. This new business opportunity is expected to generate a
continuous stream of revenues in the coming years. Since the FDA's approval of
applying bacteriophages as food additives, we received numerous inquiries from
producers who understand the commercial potential of this innovative, safe and
environment-friendly solution for the control of bacterial contaminations".
Dr Mandeville added "Biophage is continuously seeking strategic partnerships
for the co-development, out-licensing and commercialization of its phage-based
proprietary approach for the detection, prevention and control of deadly
About Biophage Pharma Inc.
Biophage Pharma is a high potential, revenue-driven Canadian
biotechnology company focused on the development of innovative phage-based
products and technologies for the detection, prevention and control of
bacterial infections. Founded in 1995, Biophage operates three divisions:
(1) The Biosensors division for the development and commercialization of
Biosensors, more particularly a portable PDS96(R) Biosensor which is now in
the pre-commercialization stage; (2) The phage therapy division for the
prevention and control of bacterial contaminations in the medical, veterinary
and environment fields; (3) The Immunotox Labs division, which provides
services in Immunogenicity and Immunotoxicity, Beryllium sensitivity testing
and MELISA(R) testing for the detection of sensitization to more than
200 different allergens including metals, penicillin, gluten and pollens.
(www.biophagepharma.net ; www.immunotoxlabs.com)
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Biophage Pharma Inc.: Rosemonde Mandeville,
M.B., Ch.B., PhD., President and Chief Executive Officer, (514) 496-1488,
email@example.com; Renmark Financial Communications
Inc.: Christine Stewart, firstname.lastname@example.org; Maurice Dagenais,
email@example.com; (514) 939-3989, Fax: (514) 939-3717,